# Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women

> **NCT00543634** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 30 (estimated)

## Conditions studied

- Postmenopause

## Interventions

- **DRUG:** Premarin/MPA
- **DRUG:** Premarin/MPA
- **DRUG:** Provera 10 mg

## Key facts

- **NCT ID:** NCT00543634
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2010-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543634, "Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00543634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*